This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Health Stocks in Motion

Shares of ViroPharma (VPHM) were among the best-performing health-related stocks Monday, rising 11% after the pharmaceutical company posted third-quarter earnings and sales that trounced Wall Street expectations.

The company earned $18.7 million, or 31 cents a share, on sales of $35.8 million. Analysts polled by Thomson First Call expected earnings of 21 cents a share and sales of $29.5 million. In the year-ago quarter, the company had a loss of $3.3 million, or 13 cents a share, on sales of $398,000. The company attributed the improved results to Vancocin, a colitis treatment. Vancocin had third-quarter sales of $35.7 million, with prescriptions up 36% from the year-earlier period.

ViroPharma increased its full-year Vancocin sales projection to $120 million to $123 million from its August forecast of $100 million to $105 million. Analysts expect sales of $119.8 million. Shares recently were trading up $2.27 to $23.26.

Dendreon (DNDN) climbed 8% after the company's Provenge prostate cancer treatment received fast-track status from the Food and Drug Administration. The designation, given for drugs that address an unmet medical need and treat life-threatening conditions, allows Dendreon to submit its biologics license application for Provenge on a rolling basis. Shares rose 45 cents to $6.03.

Shares of China Medical Technologies (CMED) rose 10% after the medical device company posted large year-over-year gains in second-quarter earnings and sales. China Medical earned $5.3 million, or 22 cents per American depositary share, on sales of $10.9 million. Earnings during the recent period jumped 61.3% while sales increased by 81.6%. The lone analyst forecast called for earnings of 19 cents a share and sales of $10.4 million. "The strong growth of our sales of the ECLIA system since its introduction in September 2004 contributed to the substantial year-over-year growth in both our net revenues and net income for the quarter," the company said.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,262.56 +89.32 0.55%
S&P 500 1,842.98 +12.37 0.68%
NASDAQ 4,034.1610 +11.4670 0.29%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs